Efficacy and safety of mesenchymal stem cell therapy for ovarian ageing in a mouse model

Wendi Pei,Lin Fu,Wenhuan Guo,Yibo Wang,Yong Fan,Rui Yang,Rong Li,Jie Qiao,Yang Yu
DOI: https://doi.org/10.1186/s13287-024-03698-0
2024-04-04
Stem Cell Research & Therapy
Abstract:Ovarian ageing is one of the major issues that impacts female fertility. Mesenchymal stem cell (MSC)-based therapy has made impressive progress in recent years. However, the efficacy and safety of MSCs, as nonautologous components, remain to be further verified.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?
The paper aims to address the issue of declining female fertility due to ovarian aging. Specifically, the researchers evaluated the therapeutic effects and safety of mesenchymal stem cells (MSCs) in a mouse model of ovarian aging, comparing the effects of two sources of MSCs—umbilical cord-derived mesenchymal stem cells (UC-MSCs) and adipose tissue-derived mesenchymal stem cells (AD-MSCs). The main objective is to verify the efficacy and safety of allogeneic MSCs in treating ovarian aging, providing more evidence for future clinical applications. The study involved transplanting these two types of MSCs into a mouse model of ovarian aging to observe their effects on ovarian function improvement. Various experimental methods were used to assess the safety of MSCs, including carcinogenicity, acute toxicity, immunogenicity, and in vivo distribution. The results showed that both AD-MSCs and UC-MSCs demonstrated significant therapeutic effects and high safety.